JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallo, I.
Right arrow Articles by Artinano, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallo, I.
Right arrow Articles by Artinano, E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 92, 14-20, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Six- to ten-year follow-up of patients with the Hancock cardiac bioprosthesis. Incidence of primary tissue valve failure

I Gallo, F Nistal and E Artinano

From June, 1974, through June, 1978, 547 porcine xenografts (299 mitral, 239 aortic, eight tricuspid, and one pulmonary) were inserted in 459 selected patients who survived the operation and were considered at risk for primary tissue valve failure. Ninety-two instances of primary tissue valve degeneration occurred in 82 of the 459 patients. In patients operated on 10 years ago, 28% of the valves implanted in the mitral position (5/18) and 33% in the aortic position (4/12) failed. These percentages decreased to 24% (21/89) and 26% (15/57) for those implanted in 1975, 15% (13/85) and 16% (9/57) for those implanted in 1976, 13% (9/71) and 15% (12/82) for 1977, and 8% (3/36) and 3% (1/31) for 1978. None of the tricuspid or pulmonary valves have failed. The rate of valve survival without primary degeneration was 70% +/- 6% for the mitral and 69% +/- 7% for the aortic prostheses at 10 years of follow-up. Of the 10 valves implanted in patients younger than 20 years of age, 40% of the mitral and 60% of the aortic valves failed. This rate is 26% for mitral and 42% for aortic for the 21 to 30 year group, 20% and 19% for 31 to 40 years, 9% and 13% for 41 to 50 years, 20% and 6% for 51 to 60 years, and 11% and 0% for 61 to 70 years. The average interval between placement and explantation or death was 74 months (range 10 to 112) for valves in the mitral position and 78 months (range 13 to 117) for valves in the aortic position. We believe these current data should have some bearing of practical import not only when comparing different types of bioprostheses but especially when recommending the appropriate valve replacement for the individual patient.


This article has been cited by other articles:


Home page
HeartHome page
P. Groves
VALVE DISEASE: Surgery of valve disease: late results and late complications
Heart, December 1, 2001; 86(6): 715 - 721.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. C. McGiffin, A. J. Galbraith, M. F. O'Brien, G. J. McLachlan, D. C. Naftel, P. Adams, S. Reddy, and L. Early
AN ANALYSIS OF VALVE RE-REPLACEMENT AFTER AORTIC VALVE REPLACEMENT WITH BIOLOGIC DEVICES
J. Thorac. Cardiovasc. Surg., February 1, 1997; 113(2): 311 - 318.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1986 by The American Association for Thoracic Surgery.